Nasdaq

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the U.S. commercial launch of Brekiya® (dihydroergotamine ...
Nasdaq

Amneal Pharmaceuticals Receives FDA Approval for Brekiya®, First DHE Autoinjector for Self-Administration in Migraine and Cluster Headache Treatment

Amneal Pharmaceuticals has received FDA approval for Brekiya®, the first and only dihydroergotamine (DHE) autoinjector designed for patients to self-administer for acute migraine and cluster headaches ...
Business Wire

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, today announced the advancement of two key strategic ...
MedPage Today

FDA Approves Auto-Injector for Migraine, Cluster Headache

The FDA approved dihydroergotamine (DHE) mesylate injection (Brekiya) to treat acute migraine (with or without aura) and cluster headaches in adults, Amneal Pharmaceuticals announced Thursday. The ...